IGC Pharma

We are a clinical stage pharmaceutical company, formerly known as India Globalization Capital, Inc.

About IGC Pharma (dba IGC):

IGC Pharma is an AI-powered, clinical-stage biotechnology company focused on developing innovative treatments for Alzheimer's disease and transforming patient care with fast-acting, safe, and effective solutions. Our portfolio includes the TGR family, including TGR-63, which targets amyloid plaques, a hallmark of Alzheimer's. The IGC-C and IGC-M platforms are advancing in preclinical studies, focusing on metabolic disorders, tau proteins, early plaque formation, and multiple disease hallmarks. Our lead therapeutic candidate, IGC-AD1, is a cannabinoid-based treatment currently in a Phase 2 trial for agitation in dementia associated with Alzheimer's (clinicaltrials.gov, NCT05543681). Clinical data for IGC-AD1 demonstrated that it has the potential to transform patient care by offering faster-acting and more effective relief compared to traditional medications. Additionally, our AI models are designed to predict potential biomarkers for the early detection of Alzheimer's, optimize clinical trials, and predict receptor affinity, among others. With 28 patent filings and a commitment to innovation, IGC Pharma is dedicated to advancing pharmaceutical treatments and improving the lives of those affected by Alzheimer's and related conditions.

10/07/2025

Redefining what’s possible in Alzheimer’s research.

IGC Pharma reports preclinical data for IGC-1C, a drug candidate that targets the tau protein’s liquid–liquid phase separation (LLPS), an early and critical event in the development of Alzheimer’s disease.

By acting before toxic tangles form, IGC-1C introduces a potentially groundbreaking therapeutic strategy to halt disease progression at its roots.

“IGC-1C can potentially target a key and early pathological event in Alzheimer’s disease,” said Ram Mukunda, CEO of IGC Pharma. “By intervening at the phase separation stage, we aim to prevent the formation of toxic tau aggregates and redefine the treatment landscape.”

09/30/2025

IGC Pharma has added Ichor Research in Syracuse, New York, led by Principal Investigator Dr. Karl F. Hafner, M.D., as a new site for the Phase 2 CALMA trial of IGC-AD1 for agitation in Alzheimer’s disease.

For more information about the Syracuse site, please contact Kristen Stebbins, VP of Clinical Trial Operations, at kstebbins@ichorlifesciences.com or 315-904-5004.

This addition reflects our mission to make research more inclusive and impactful, advancing therapies designed to improve quality of life for Alzheimer’s patients and their families.

09/18/2025

What the future of Alzheimer’s care looks like?

In a recent IMS Interview spotlight, our CEO and founder Ram Mukunda shared how IGC Pharma is advancing science and innovation to answer that question.

He discussed the expansion of our Phase 2 CALMA clinical trial with IGC-AD1, our proprietary cannabinoid-based investigational drug targeting agitation in Alzheimer’s patients, its potential as a disease-modifying therapy, and the development of our synthetic molecules TGR-63 and IGC-M3. These programs reflect our multi-pronged strategy to address both the symptoms and the underlying biology of Alzheimer’s.

Ram also highlighted MINT-AD, our first-of-its-kind AI-powered tool designed to help physicians stratify Alzheimer’s risk factors and predict cognitive decline, making early detection more accessible.

Together, these initiatives demonstrate IGC Pharma’s commitment to combining rigorous research, innovative therapies, and advanced technology to improve outcomes and bring hope to patients and families affected by Alzheimer’s.

To read the full interview, follow this link: https://www.linkedin.com/pulse/advancing-therapies-ai-tools-alzheimers-disease-culqe/

09/08/2025

At IGC Pharma (NYSE American: IGC), we believe that innovation must be both powerful and shareable.

We are proud to have been recognized in the NIA PREPARE Challenge for our clean and reusable AI code that advances early Alzheimer’s detection.

This achievement underscores our commitment to scientific rigor, open collaboration, and scalable impact, creating tools that accelerate global progress in Alzheimer’s research while strengthening long-term shareholder value.

Watch our official pitch here: https://www.youtube.com/watch?v=arsMh0hGTjQ&t=1502s

09/03/2025

Expanding our reach, strengthening our mission

The CALMA Phase 2 trial is now enrolling patients at Island Health’s Royal Jubilee Hospital in Victoria, British Columbia, marking an important milestone as the study grows across North America

This expansion reinforces our commitment to advancing IGC-AD1, a novel therapy candidate for agitation in Alzheimer’s, and to collaborating with leading research institutions to bring innovative solutions to patients and caregivers

09/02/2025

Expanding innovation in neurological care.

We’re proud to share that IGC Pharma has received a Notice of Allowance from the USPTO for a novel microdose-based treatment (IGC510) targeting stammering, stuttering, and Tourette’s syndrome.

This achievement reflects our commitment to developing therapies that not only address unmet medical needs but also prioritize safety and quality of life for patients and caregivers.

09/01/2025

September is World Alzheimer’s Month

A time to raise global awareness of a disease that affects over 55 million people worldwide and impacts not only memory, but also behavior, emotions, and relationships.

Behavioral and emotional changes, such as anxiety, agitation, apathy, or sudden mood shifts, are often among the first signs families notice, and can be just as challenging as memory loss.

At IGC Pharma, we’re advancing research focused on these symptoms, with the goal of improving quality of life for patients and caregivers. This month, and every month, we reaffirm our commitment to driving innovation and hope in Alzheimer’s care.

08/28/2025

We’re pleased to share that Ascendiant Capital Markets has issued a coverage report on IGC Pharma. The analysis recognizes Q1 progress and points to positive clinical data in 2025 as strong catalysts, raising the price target to $4.50.

The full report is available directly from Ascendiant Capital Markets: https://ascendiant.com/research-reports/igc-q1-fy26/

08/26/2025

Expanding CALMA. Advancing Research. Impacting Lives.

We’re proud to announce the expansion of our CALMA Phase 2 trial with a new clinical site at Lynn Health Science Institute in Oklahoma City, led by Principal Investigator Dr. Carl Griffin.

This milestone helps us reach more patients and families affected by Alzheimer’s, advancing our mission to bring innovative treatments where they’re needed most.

08/22/2025

Shaping the Future of Alzheimer’s Care: Our First Quarter in Review

AI-powered tools. Cannabinoid and small molecules platforms. Shaping new ways to understand and address Alzheimer’s disease.

Our dedicated team and partners are committed to delivering progress that brings meaningful value to patients, caregivers, and stakeholders.

08/13/2025

Alzheimer’s disease impacts millions worldwide, yet effective treatment options remain limited. At IGC Pharma, we’re working to change that by advancing therapies that address both the symptoms and the root causes of the disease.

Our pipeline includes IGC-AD1, a proprietary cannabinoid-based therapy in Phase 2 trials, and IGC-M3, a next-generation small molecule in preclinical development. Together, they reflect our commitment to science-driven innovation in Alzheimer’s care.

Beyond the lab, our focus is on transforming promising data into meaningful outcomes for patients, caregivers, and communities affected by neurodegeneration.

At IGC Pharma, we’re redefining what’s possible in Alzheimer's research.

Address

Potomac, MD

Telephone

+13019830998

Website

https://igcpharma.com/

Alerts

Be the first to know and let us send you an email when IGC Pharma posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.